Mushrooms and Parkinson's Disease: Neuroprotective Research

Mushrooms & Parkinson's Disease

3 independent model systems

A 2025 study validated ergothioneine's neuroprotective effects across Drosophila, mouse, and human patient-derived iPSC neurons simultaneously — the most multi-modal mushroom-compound PD evidence yet.

Tng et al., Journal of Neurochemistry, 2025

No human trials

all current mushroom-Parkinson's evidence is preclinical: animal models or cell culture

Lion's mane + reishi

the two most-studied medicinal species with independent MPTP mouse model datasets

Ergothioneine

the common dietary compound found in all culinary mushroom species linking to dopaminergic protection

Tng et al., Journal of Neurochemistry, 2025

View as image ↗

No one has run a randomized controlled trial testing mushroom consumption in Parkinson's disease patients. That boundary matters and should be stated first. What does exist — across a decade of preclinical research from multiple countries, multiple species, and multiple research groups — is a convergent case that certain mushroom compounds protect the specific type of neuron that Parkinson's disease destroys. This is the article that maps that entire case: what has been studied, what the evidence shows, and where the honest limits are. It sits within the broader pillar on mushrooms and brain health and is the anchor for a five-article cluster on this topic.

The story runs from mushrooms and Parkinson's disease in animal models through to a unifying biological thread that connects culinary and medicinal species alike — a thread that several research groups have now identified independently.

Several Species, Multiple Research Groups, One Target

The research on mushrooms and Parkinson's disease is not the work of a single lab pursuing a single idea. A 2015 review by Ds et al. in Evidence-Based Complementary and Alternative Medicine surveyed the neuroprotective properties of culinary-medicinal mushrooms — lion's mane, reishi, maitake, shiitake — across multiple research groups and documented consistent evidence of antioxidant, anti-inflammatory, and neurotrophic mechanisms relevant to Parkinson's, Alzheimer's, and other neurodegenerative diseases.^[1]

That 2015 review was a starting-point synthesis. The decade since has sharpened the mechanistic picture considerably. A comprehensive 2022 review by He et al. in Molecules mapped bioactive mushroom compounds — ergothioneine, erinacines, hericenones, ganoderic acids, polysaccharides — across PD, Alzheimer's, and ALS models, identifying which have validated neuroprotective mechanisms and where clinical translation gaps remain.^[2]

What the two reviews bracket is a decade of convergence. Multiple independent research groups studying different species arrived at a common conclusion: mushroom compounds reach the right brain structures, activate the right protective pathways, and attenuate dopaminergic neuron loss in the models that most closely approximate Parkinson's disease. The following sections go through the specific evidence, species by species and compound by compound.

Lion's Mane: Erinacine A and the MPTP Mouse Model

The most studied mushroom in the Parkinson's preclinical literature is Hericium erinaceus — lion's mane. And the most important distinction in that literature is one that most consumers never hear: the evidence centers on erinacine A, a compound concentrated in the mycelium, not the fruiting body that most commercial supplements use.

Li et al.'s 2018 review documented that erinacine A-enriched H. erinaceus mycelia improved dopaminergic lesions and reduced oxidative stress in the striatum and substantia nigra of MPTP-treated mice — the standard animal model of Parkinson's disease.^[3] MPTP selectively destroys dopaminergic neurons in the substantia nigra, mimicking the neurodegeneration pattern of PD. Li's synthesis of this data confirmed that erinacine A crosses the blood-brain barrier, making oral administration plausibly effective.

Bäumer et al., in a 2025 narrative review published in Antioxidants, provided the most comprehensive recent synthesis of lion's mane neuroprotective mechanisms.^[4] Their review covered NGF stimulation, anti-neuroinflammatory activity, antioxidant properties including ergothioneine content, erinacine A MPTP data, and the clinical evidence gaps. The Bäumer review is notable for being explicit about what the data does not yet support: no human Parkinson's disease trial with lion's mane has been run.

Mycelium vs. Fruiting Body: A Distinction That Matters

Erinacines are concentrated in mycelium. Hericenones — the other neuroprotective compound class in lion's mane — are concentrated in the fruiting body. Commercial lion's mane products are mostly fruiting body extracts. This creates a gap between the MPTP preclinical data (which used erinacine-enriched mycelium) and what most supplements actually contain. For anyone evaluating lion's mane supplements in the context of this research, the mycelium vs. fruiting body distinction is the first question to ask. For a species-by-species breakdown of this and other practical distinctions, see Which Mushrooms Show Promise for Parkinson's?.

Reishi: Mitochondrial Protection in the MPTP Model

Ganoderma lucidum — reishi — has one of the cleaner single-study datasets in the mushroom-PD literature.

Ren et al., published in Frontiers in Aging Neuroscience in 2019, found that reishi extract significantly improved locomotor performance in MPTP mice and increased tyrosine hydroxylase expression in the substantia nigra pars compacta.^[5] Tyrosine hydroxylase is the key enzyme in dopamine synthesis and a direct marker of dopaminergic neuron health. The mechanism identified involved AMPK/mTOR and PINK1/Parkin signaling — pathways that regulate mitochondrial quality control and autophagy, both compromised in Parkinson's disease.

Reishi has also been studied for its anti-neuroinflammatory properties in MPTP models — microglial suppression and nigrostriatal pathway protection. The mechanistic detail on both angles is covered in Mushroom Compounds and Dopaminergic Neuron Protection.

The Ergothioneine Thread: Connecting Culinary and Medicinal Mushrooms

Here is the aspect of the mushroom-Parkinson's evidence that no competitor has assembled: there is a common thread running through both culinary and medicinal mushroom species, and it is ergothioneine.

Ergothioneine is found in all edible mushroom species — not just lion's mane or reishi, but king oyster, shiitake, button, cremini, portobello, and maitake. It is the compound for which the human body evolved a dedicated transporter (OCTN1), and that transporter is expressed in dopaminergic neurons. In other words: the cells that Parkinson's disease destroys are equipped with a dedicated mechanism to accumulate this dietary compound from mushrooms.

A 2024 review by Kell et al. in Free Radical Biology and Medicine proposed this connection as a formal hypothesis: that age-related ergothioneine deficiency — driven by declining mushroom consumption and declining OCTN1 expression with age — may be a causal upstream factor in Parkinson's disease and other neurodegenerative diseases.^[6] The epidemiological data available by 2024 supported this hypothesis in outline: Parkinson's disease patients consistently show lower plasma ergothioneine than healthy controls, and a 470-person Singapore cohort documented the inverse correlation between plasma ergothioneine and neurodegeneration markers.

For the full epidemiological story, see Ergothioneine and Parkinson's Disease Risk: Evidence Review.

Tng 2025: The Most Comprehensive Ergothioneine Study Yet

The strongest mechanistic evidence for ergothioneine in Parkinson's disease models was published in 2025 by Tng et al. in the Journal of Neurochemistry.^[7] Their experiment tested ergothioneine treatment in three independent model systems simultaneously: Drosophila fruit flies with parkin and LRRK2 mutations, mouse PD models, and human LRRK2 G2019S iPSC-derived dopaminergic neurons from actual Parkinson's patients.

Ergothioneine improved outcomes in all three. The Drosophila showed better climbing scores and less dopaminergic neuron loss. Mouse models showed reduced pathological phenotypes. The human patient-derived neurons showed enhanced survival. Three systems, three species (fruit fly, mouse, human cell), one direction of effect.

This multi-model convergence is the key to the Tng 2025 finding. Single-model results in neurodegenerative disease research have a poor record of translating to different models or to humans. A finding that holds in a fly and a mouse and a human cell culture simultaneously carries substantially more weight than any one of those findings in isolation.

The Tng 2025 study is, at this writing, the most comprehensive experimental validation of ergothioneine's protective effects in Parkinson's disease models. For a deeper mechanistic walkthrough of how these compounds protect dopaminergic neurons at the molecular level, see Mushroom Compounds and Dopaminergic Neuron Protection.

The Population Signal From Singapore

The laboratory evidence for dopaminergic neuroprotection is one half of the case. The other half comes from population data.

Cheah et al.'s 2021 Singapore Memory Clinic study of 470 elderly subjects found that low plasma ergothioneine was inversely correlated with neurodegeneration markers — brain atrophy, white matter lesions, cerebrovascular disease, and Parkinson's disease burden.^[8] This is cross-sectional data, meaning it cannot establish causality. But it connects the laboratory mechanistic finding (ergothioneine protects dopaminergic neurons) to a population-level signal (people with lower ergothioneine have more neurodegeneration).

The Singapore context matters. Singapore's population eats more mushrooms per capita than most Western countries, and a related Singapore cohort found that eating two or more portions of mushrooms per week was associated with lower odds of mild cognitive impairment. The plasma ergothioneine data in the Cheah study provides a proposed mechanism for why that association exists. For more on the Singapore mushroom consumption research, see The Singapore Mushroom Study: Mushroom Intake and Cognitive Decline.

What the Evidence Does Not Yet Show

The honest limits of this research body are specific:

No human clinical trial. Every study cited above is preclinical — animal models, cell cultures, or observational population data. No randomized controlled trial has given lion's mane, reishi, ergothioneine, or any mushroom compound to Parkinson's disease patients and measured outcomes.

Animal models don't perfectly predict human disease. MPTP-induced dopaminergic neuron death is a useful model, but it does not capture the full complexity of Parkinson's disease, including the role of alpha-synuclein aggregation, the genetic heterogeneity of PD, or the decades-long progression before diagnosis.

Ergothioneine plasma levels are not the same as dietary ergothioneine intake. The population associations between low plasma ergothioneine and neurodegeneration don't prove that eating more mushrooms will raise levels sufficiently, or that raising levels will produce the protection seen in laboratory models.

These are specific, addressable limitations — which is different from saying the evidence is weak. A decade of convergent preclinical findings across multiple species, multiple compounds, and multiple research groups, supported by population-level epidemiological signals and the most multi-modal animal evidence yet from 2025, represents a meaningful evidence base. It is not clinical-trial-level evidence. It is a well-constructed scientific case that warrants human trials.

For a practical summary of which mushroom species show the most research support and what dietary strategies the evidence can and cannot justify, see Mushrooms and Parkinson's: Ergothioneine Deficiency and Dopaminergic Protection and Best Mushrooms for Brain Health in Older Adults.

The Bottom Line

Multiple mushroom species — primarily lion's mane (via erinacine A mycelium extract) and reishi (via mitochondrial and anti-inflammatory mechanisms) — have demonstrated dopaminergic neuroprotection in MPTP mouse models over a decade of independent research. Ergothioneine, found in all culinary mushroom species, connects these findings to population data: PD patients have lower plasma ergothioneine, and a 2025 multi-model study validated its protective effects across Drosophila, mouse, and human patient-derived neurons simultaneously. No human Parkinson's disease trial has tested mushroom compounds.

Frequently Asked Questions

Can eating mushrooms help with Parkinson's disease?

There is no clinical trial evidence that eating mushrooms helps Parkinson's disease patients. What exists is preclinical evidence: lion's mane mycelium extract protected dopaminergic neurons in MPTP mouse models, reishi extract improved motor function in the same model, and ergothioneine — found in all culinary mushroom species — protected human patient-derived dopaminergic neurons in a 2025 lab study. Population data shows PD patients have lower plasma ergothioneine than healthy controls.

What research supports mushrooms for Parkinson's?

The strongest preclinical evidence comes from two areas: MPTP mouse model studies with lion's mane (erinacine A-enriched mycelium) and reishi extract, published by independent research groups between 2018 and 2022; and ergothioneine research, including a 2025 study that validated protective effects across Drosophila, mouse, and human LRRK2 patient-derived iPSC neurons. Population data from Singapore also links low ergothioneine to higher neurodegeneration burden.

Which mushrooms are best for Parkinson's disease?

The preclinical evidence is strongest for lion's mane mycelium (via erinacine A — not available in most fruiting-body supplements) and reishi, which has two independent MPTP datasets. Culinary mushrooms — king oyster, shiitake, button — have the highest ergothioneine content, which may matter more at the population level for dietary prevention than medicinal extracts. No mushroom has human clinical trial evidence for Parkinson's disease.

Do mushrooms prevent Parkinson's disease?

Not proven. No human trial has tested mushroom consumption as a Parkinson's prevention strategy. Population data from Singapore shows people with lower plasma ergothioneine — a compound found primarily in mushrooms — have more neurodegeneration markers and more Parkinson's disease burden. Whether eating more mushrooms raises ergothioneine sufficiently to reduce PD risk in humans is a question that has not been directly tested.

What natural remedies show promise for Parkinson's disease?

Among dietary compounds, ergothioneine from mushrooms has accumulated the most mechanistically coherent evidence: OCTN1-dependent transport into dopaminergic neurons, antioxidant activity confirmed in human patient-derived cells, and multi-model animal validation in 2025. Coenzyme Q10, curcumin, and omega-3 fatty acids have also been studied in Parkinson's disease models, with mixed results. No dietary compound has established efficacy in a human Parkinson's disease clinical trial.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3RTHM-00973·Li, I-Chen et al. (2018). “Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines..” Behavioural neurology.Study breakdown →PubMed →↩
4. 4. Source details for this reference are not yet available.
5. 5RTHM-01118·Ren, Zhi-Li et al. (2019). “Ganoderma lucidum extract ameliorates MPTP-induced parkinsonism and protects dopaminergic neurons from oxidative stress via regulating mitochondrial function, autophagy, and apoptosis..” Acta pharmacologica Sinica.Study breakdown →PubMed →↩
6. 6. Source details for this reference are not yet available.
7. 7RTHM-02195·Tng, Teddy J W et al. (2025). “Ergothioneine Treatment Ameliorates the Pathological Phenotypes of Parkinson's Disease Models..” Journal of neurochemistry.Study breakdown →PubMed →↩
8. 8. Source details for this reference are not yet available.